[
  {
    "text": "project blue sky inc &amp; ors v australian broadcasting authority  statutes",
    "id": "cp0.0",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "construction",
    "id": "cp0.1",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "reconciliation of conflicting provisions",
    "id": "cp0.2",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "intention of legislature",
    "id": "cp0.3",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "presumption that provisions intended to achieve consistent goals",
    "id": "cp0.4",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "leading and subordinate provisions",
    "id": "cp0.5",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "grammatical meaning and legal meaning.  statutes",
    "id": "cp0.6",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "construction",
    "id": "cp0.7",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "acts done in breach of a condition regulating a statutory power",
    "id": "cp0.8",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "whether invalid",
    "id": "cp0.9",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "mandatory and directory provisions",
    "id": "cp0.10",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "purpose-based test.  media law",
    "id": "cp0.11",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "television",
    "id": "cp0.12",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "regulation of programming",
    "id": "cp0.13",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "australian broadcasting authority",
    "id": "cp0.14",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "standard prescribing australian content requirements",
    "id": "cp0.15",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "whether inconsistent with legislative requirement that functions be performed consistently with australia's international obligations.  media law",
    "id": "cp0.16",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "television",
    "id": "cp0.17",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "regulation of programming",
    "id": "cp0.18",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "australian broadcasting authority",
    "id": "cp0.19",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "power to make standards that \"relate to ... the australian content of programs\"",
    "id": "cp0.20",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "whether restricted to standards conferring preferential treatment.  trade law",
    "id": "cp0.21",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "australia new zealand closer economic relations trade agreement.  broadcasting services act 1992 (cth), ss 3 , 122 , 158, 160.  broadcasting services (transitional provisions and consequential amendments) act 1992 (cth), s 21.  tasker v fullwood [1978] 1 nswlr 20 at 23-24 applied.",
    "id": "cp0.22",
    "type": "cited",
    "from": "[1998]"
  },
  {
    "text": "high court",
    "id": "cp1.0",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "jurisdiction",
    "id": "cp1.1",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "statutory commodity marketing board",
    "id": "cp1.2",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "power to make regulations necessary or convenient for carrying out or giving effect to act",
    "id": "cp1.3",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "regulations empowering high court to hear disputed election petitions",
    "id": "cp1.4",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "validity",
    "id": "cp1.5",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "the constitution (63 &amp; 64 vict. c. 12), ss. 51 (i.) (xxxix.), 76",
    "id": "cp1.6",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "apple and pear organization act, 1938-1966 (cth), s. 27",
    "id": "cp1.7",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "apple and pear organization (election of board) regulations 1948, regs. 38, 40.",
    "id": "cp1.8",
    "type": "cited",
    "from": "[1971]"
  },
  {
    "text": "marketing of primary products",
    "id": "cp2.0",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "egg and egg pulp marketing board",
    "id": "cp2.1",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "regulation",
    "id": "cp2.2",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "validity",
    "id": "cp2.3",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "prohibition against any person placing eggs in cold storage without consent of board",
    "id": "cp2.4",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "not restricted to eggs vested in the board",
    "id": "cp2.5",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "statutory power to make regulations",
    "id": "cp2.6",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "for purposes necessary or expedient for the administration of the act or for carrying out the objects of the act",
    "id": "cp2.7",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "regulating the storage of the commodity",
    "id": "cp2.8",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "marketing of primary products acts 1935-1953 (no. 4337",
    "id": "cp2.9",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "no. 5710) (vict.), ss. 18 (1) (c), 43 (1) (b) (iv)",
    "id": "cp2.10",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "egg and egg pulp marketing board regulations 1953, reg. 44.",
    "id": "cp2.11",
    "type": "cited",
    "from": "[1957]"
  },
  {
    "text": "regulation",
    "id": "cp3.0",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "excise",
    "id": "cp3.1",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "duty",
    "id": "cp3.2",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "liability for payment",
    "id": "cp3.3",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "fixed by statute",
    "id": "cp3.4",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "extension of liability by regulation",
    "id": "cp3.5",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "validity",
    "id": "cp3.6",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "excise act 1901-1949 (no. 9 of 1901",
    "id": "cp3.7",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "no. 46 of 1949), s. 164",
    "id": "cp3.8",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "excise regulations 1925-1948 (s.r. no. 181 of 1925",
    "id": "cp3.9",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "no. 95 of 1948), reg. 188.",
    "id": "cp3.10",
    "type": "cited",
    "from": "[1951]"
  },
  {
    "text": "patents",
    "id": "cp6.0",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "validity",
    "id": "cp6.1",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer",
    "id": "cp6.2",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "patentee also held previous patent for the racemate",
    "id": "cp6.3",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "both the racemate and the enantiomer, drugs for the treatment of depression",
    "id": "cp6.4",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "(+)-citalopram claimed to be therapeutically more effective than citalopram",
    "id": "cp6.5",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "challenge to validity of claim for (+)-citalopram",
    "id": "cp6.6",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "construction of claim",
    "id": "cp6.7",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "whether for (+)-enantiomer as an independently existing molecule or whether also for (+)-enantiomer when part of racemate",
    "id": "cp6.8",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "whether claim for (+)-enantiomer anticipated by patent for citalopram",
    "id": "cp6.9",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "whether (+)-enantiomer as an independent molecule was obvious",
    "id": "cp6.10",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "australian test for obviousness",
    "id": "cp6.11",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "application of that test to product claims for the (+)-enantiomer, and to method claim for the method of obtaining it",
    "id": "cp6.12",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "lack of utility",
    "id": "cp6.13",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "product claim for a dosage that, inter alia , was less than and more than a useful dosage range. held : (1) upon its proper construction, product claimed was the independently existing enantiomer; (2) the invention of the independently existing enantiomer was not anticipated by the patent for the racemate; (3) the australian \"matter of routine\" test for obviousness, when applied to the invention of the product, equated to the question whether those skilled in the art, as a matter of routine, would have had the goal of obtaining separate enantiomers in the expectation that one would be a desirable drug for the treatment of depression; (4) one of the product claims relating to dosage failed test of utility; (5) on the evidence, neither the (+)-enantiomer nor the method for obtaining it was obvious at the priority date.   patents",
    "id": "cp6.14",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "extension of term",
    "id": "cp6.15",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer",
    "id": "cp6.16",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "patentee also held previous patent for the racemate",
    "id": "cp6.17",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "both the racemate and the enantiomer, drugs for the treatment of depression",
    "id": "cp6.18",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "(+)-citalopram claimed to be therapeutically more effective than citalopram",
    "id": "cp6.19",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "both cipramil (goods based on racemic citalopram) and lexapro (goods based on (+)-citalopram) entered in australian register of therapeutic goods (artg)",
    "id": "cp6.20",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "application for extension of term of patent for (+)-citalopram",
    "id": "cp6.21",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "commissioner of patents initially granted extension sought",
    "id": "cp6.22",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "subsequently, following hearing before her delegate, decided to reduce term of extension on ground that \"first regulatory approval date\" was date when goods cipramil based on racemate had been entered in artg",
    "id": "cp6.23",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "appeal by patentee",
    "id": "cp6.24",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "opponent pharmaceutical company contending that no extension at all should have been granted because application for extension had been made outside six month period following date of first inclusion in artg of goods containing the (+)-enantiomer, namely, cipramil, of which the active pharmaceutical substance was the racemate",
    "id": "cp6.25",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "questions of proper construction of patents act 1990 (cth) ss 70 , 71 , 77",
    "id": "cp6.26",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "whether goods based on racemate \"contain\" individual enantiomer",
    "id": "cp6.27",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "meaning of \"first regulatory approval date\" in s 70(5) of act. held : (1) cipramil contained pharmaceutical substance (+)-citalopram; (2) application for extension of term of patent had not been made within six months of first inclusion in artg of cipramil; (3) in circumstances, commissioner had lacked power to grant any extension to term of patent; (4) register of patents to be rectified by removal of particulars of extension.   patents",
    "id": "cp6.28",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "infringement",
    "id": "cp6.29",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer",
    "id": "cp6.30",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "generic company applying to therapeutic goods administration (tga) for registration of generic drug based on (+)-enantiomer of citalopram",
    "id": "cp6.31",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "whether doctrine of \"mechanical equivalents\" or \"non-essential integers\" applicable to method of obtaining pharmaceutical compound",
    "id": "cp6.32",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "generic pharmaceutical company producing generic drug only for purpose of applying for regulatory approval",
    "id": "cp6.33",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "s 78(2) of patents act 1990 (cth).",
    "id": "cp6.34",
    "type": "citing",
    "from": "[2008]"
  },
  {
    "text": "intellectual property",
    "id": "cp9.0",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "patents",
    "id": "cp9.1",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "whether extension of time for patent valid",
    "id": "cp9.2",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "whether commissioner misconstrued s 70 of the patents act in extending the term of the patent",
    "id": "cp9.3",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "registration and listing of goods under the therapeutic goods act",
    "id": "cp9.4",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "whether the first regulatory approval date is the date on which substance was entered into the part of the therapeutic register relating to registered goods or the date on which the substance was entered into the therapeutic register relating to listed goods  practice and procedure",
    "id": "cp9.5",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "appeals",
    "id": "cp9.6",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "leave to appeal required for an appeal under s 158 of the patents act",
    "id": "cp9.7",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "whether clear prima facie error required in the reasons of the primary judge",
    "id": "cp9.8",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "patents",
    "id": "cp10.0",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "date for calculation of extension of term of patents relating to pharmaceutical substances",
    "id": "cp10.1",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "\"first inclusion in the australian register of therapeutic goods\" not limited to regulatory approval to market pharmaceutical substance in australia",
    "id": "cp10.2",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "correct date if no \"pre-tga marketing approval\" granted is first entry in the australian register of therapeutic goods, including an entry as listed goods for export only statutory construction",
    "id": "cp10.3",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "extrinsic materials relevant to context and legislative history",
    "id": "cp10.4",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "materials equivocal on whether \"first inclusion\" means registration or listing",
    "id": "cp10.5",
    "type": "citing",
    "from": "[2006]"
  },
  {
    "text": "legislative objective that patentee should have \"effective patent life\" to exploit patent",
    "id": "cp10.6",
    "type": "citing",
    "from": "[2006]"
  }
]